KAMPOS
19.5.2020 07:02:04 CEST | Business Wire | Press release
KAMPOS , an Italian startup company, today announced the launch of a socially-responsible, environmentally friendly line of products and accessories to celebrate the history and beauty of the Mediterranean Sea. Founded by entrepreneur Alessandro Vergano, KAMPOS’ corporate vision is to “offer luxury products with a conscience, now and for generations to come.” All products are made of recycled plastic bottles, abandoned “ghost” fishing nets, or other recycled nylon and/or organic fabrics. Every product and accessory detail have been studied and designed to be sustainable. KAMPOS’ products are recycled AND are recyclable after use.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200518005003/en/
“Fashion companies have a tremendous platform from which to reach consumers in a positive manner, but few have embraced social issues as part of their business model,” said Vergano, KAMPOS’ co-founder and chief executive officer. “KAMPOS is different in that sustainability is at the core of everything we do from the selection from raw materials to product development to packaging. This means consumers will realize long-lasting performance of the products in which they invest because of enhanced durability and will be acting in a socially responsible manner with each purchase.”
Vergano’s vision for KAMPOS is to raise awareness worldwide of the impact of plastic pollution and abandoned fishing nets by offering sustainable, alternative high fashion solutions for consumers who share in the company’s mission. A percentage of KAMPOS’ revenues will be donated One Ocean Foundation (https://www.1ocean.org/en/ ), a non-profit founded in Porto Cervo, Sardinia. The joint effort is to accelerate solutions to ocean issues promoting a sustainable blue economy and enhancing knowledge through ocean literacy.
KAMPOS’ initial product line, which is all made in Italy, consists of swimsuits, shirts, t-shirts, perfumes, sunglasses, pareos (wraparounds) and accessories for men, women, and children. The company’s products are made of: Econyl, 100% regenerated nylon (filament) or certified GOTS (Global Organic Textile Standard) organic and biological cotton; and Newlife™, a unique, certified system of recycled polyester filament yarns that are 100% post-consumer bottle sourced, processed into a polymer through a mechanical -- not chemical -- process, and spun into yarn. No plastic is used in the packaging. The product line is now officially online at www.kampos.com and will be available for purchase in May. In June, KAMPOS plans to open its initial store in Porto Cervo, Sardinia (Italy) at the prestigious Promenade Du Port.
The name KAMPOS is an abbreviation of the Greek word HIPPO KAMPOS, which translates into Seahorse. In Rome and Greek cultures, the Seahorse was sacred to Neptune and Poseidon, the Sea Gods. It was considered a symbol of power, authority and good fortune with strong emotions and intuitions. Vergano launched KAMPOS in homage to his heritage and to celebrate the Mediterranean lifestyle.
KAMPOS’ innovative luxury fashion line includes active involvement from some of Italy’s more prominent creative and photography talent including the Carla Pozzi Agency and Art Director Roberto Da Pozzo in Milan. Additional information about KAMPOS, its products and accessories, are available on Pinterest , Instagram , Facebook and YouTube .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200518005003/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom